Back to results
US 2025/0375522 A1Published application
Chimeric checkpoint receptor for the use in treatment of malignant b-cell diseases
AssigneeUniversität zu Köln
InventorMarkus Chmielewski
Life of this patent
Estimating the term…
Abstract
The invention is related to a chimeric checkpoint receptor (CCR) fusion protein, a nucleic acid molecule encoding said fusion protein, a vector comprising said nucleic acid molecule, a host cell comprising said nucleic acid molecule and/or expressing the fusion protein, a method for providing said host cell, a pharmaceutical composition comprising said fusion protein, nucleic acid molecule or host cell, and said products for use as a medicament and in the treatment of B cell lymphoma.
Claims16
Fusion protein comprising:
- a) an extracellular domain comprising a polypeptide with specific affinity to CD80 and/or CD86;
- b) a transmembrane domain;
- and
- c) an intracellular domain comprising a co-stimulatory polypeptide.
1 more element
Dependencies are inferred from the claim text.